One can elucidate the entire antibody sequence by utilizing a known Complementarity-determining region (CDR) sequence in combination with the accessible Patsnap Bio Sequence Database.

Merck's recent revenue performance remains steady, with the K drug continuing to grow and earning the title of "New Generation Drug King".

Avidity Biosciences Reports Fresh Positive Results for AOC 1001, Showing Progress in Various Additional Functional Measures and Long-term Safety and Acceptability in Individuals with Type 1 Myotonic Dystrophy.

The patent and literature contain sequences of nucleic acids containing N and protein sequences containing X. I'm interested in reducing the risk of missing such sequences. Is there a recommended database where I can search for these sequences?

This article summarized the latest R&D progress of epalrestat, the Mechanism of Action for epalrestat, and the drug target R&D trends for epalrestat.

In the AAV field, common inventions involve the replacement and combination of expression-related gene regulatory elements.

Bio-Thera Solutions has made it known that its associate company, Biogen, was recently notified by FDA about the approval of TOFIDENCE (tocilizumab-bavi) in an intravenous mixture.

Novo Nordisk has nearly succeeded by relying on one metabolic domain and leveraging the power of GLP-1 alone, raising its market value from 100 billion to over 400 billion, reaching unprecedented heights on the centenary of its founding.

This article summarized the latest R&D progress of eperisone hydrochloride, the Mechanism of Action for eperisone hydrochloride, and the drug target R&D trends for eperisone hydrochloride.

Major histocompatibility complex class II (MHC II) molecules play a crucial role in the immune system by presenting antigens to CD4+ T cells.

This article summarized the latest R&D progress of erythromycin stearate, the Mechanism of Action for erythromycin stearate, and the drug target R&D trends for erythromycin stearate.

The performance of Johnson & Johnson's pharmaceutical sector is quite robust among large pharmaceutical companies, with the driving force of the two major engines - Ustekinumab and Daratumumab - being very adequate.